N-methyl-N-(2-thienyl)-acetamide | 173980-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: N-methyl-N-(2-thienyl)-acetamide
• 英文别名: N-Methyl-N-[2]thienyl-acetamid；N-methyl-N-thiophen-2-ylacetamide
• CAS: 173980-59-1
• 化学式: C₇H₉NOS
• 分子量: 155.221
• InChiKey: VOZFTRNENOJFTL-UHFFFAOYSA-N

物化性质

• 沸点：
  234.2±13.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-N-(2-thienyl)-acetamide 在 正丁基锂 、 tetraphosphorus decasulfide 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 1.0h， 生成 N-methyl-N-(2-thienyl)thiocarbamoylacetic acid
  参考文献：
  名称：

  The First Synthesis of N-Alkyl-N-Arylthiocarbamoylacetates and Acetic Acids

  摘要：

  N-Alkyl-N-arylthiocarbamoylacetates, the key intermediates for the synthesis of novel antinephritic agents, have been prepared for the first time. Some of the esters were in turn hydrolyzed to the corresponding acids, An alternative, indirect synthetic route was also developed to prepare some unusual acids.

  DOI：

  10.1080/00397910008087354
• 作为产物：
  描述：

  碘甲烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 xylene 作用下， 生成 N-methyl-N-(2-thienyl)-acetamide
  参考文献：
  名称：

  Steinkopf, Justus Liebigs Annalen der Chemie, 1914, vol. 403, p. 35

  摘要：

  DOI：

文献信息

• DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM
  申请人：OHTA Toshiharu

  公开号：US20090281074A1

  公开（公告）日：2009-11-12

  Drug compositions containing a substituted diamine compound represented by formula (1): Q 1 -Q 2 -r-N(R 1 )-Q 3 -N(R 2 )  (1) wherein Q 3 represents the following group wherein Q 5 represents an alkylene group having 4 carbon atoms, R 3 represents a hydrogen atom, and R 4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  含有以下式子（1）所代表的取代二胺化合物的药物组合物： Q1-Q2-r-N（R1）-Q3-N（R2）  （1） 其中，Q3代表以下基团： 其中，Q5代表具有4个碳原子的烷基基团，R3代表氢原子，R4代表可取代的3-6环杂环基团； 该药物组合物对于预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血凝。
• METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES
  申请人：Ohta Toshiharu

  公开号：US20100099660A1

  公开（公告）日：2010-04-22

  A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing is provided. The method includes administration of an effective amount of a compound represented by formula (1):

  提供了一种治疗脑梗塞、脑栓塞、心肌梗死、心绞痛、肺梗塞、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固的方法。该方法包括给予化合物（1）式所代表的有效量。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20060252837A1

  公开（公告）日：2006-11-09

  A compound represented by formula (1): Q 1 -Q 2 -T o -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) [wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: (wherein Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T 0 and T 1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  化合物的化学式为(1): Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4(1) [其中，R1和R2是氢原子或类似物; Q1是饱和或不饱和的、5-或6-成员的环烃基，可以被取代，或类似物; Q2是单键或类似物; Q3表示以下基团: (其中，Q5是具有1至8个碳原子的烷基或类似物); T0和T1是羰基基团或类似物]，其盐、溶剂化物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布氏病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)、体外循环期间的血栓形成或采血时的血液凝结。
• PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID
  申请人：NAGASAWA Hiroshi

  公开号：US20090192313A1

  公开（公告）日：2009-07-30

  5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid of formula (5) or a salt thereof, [F14] is prepared by reacting a compound of formula (6) or a salt thereof, with a trihalogenoacetyl halide in the presence of a base, followed by hydrolysis.

  化合物5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid或其盐[F14]的制备方法为，在碱存在下，将化合物式为(6)或其盐与三卤代乙酰卤反应，然后进行水解。
• Process for producing thiazole derivative
  申请人：Nagasawa Hiroshi

  公开号：US20070135476A1

  公开（公告）日：2007-06-14

  The present invention provides processes for producing a compound (5) based on the following reaction scheme.

  本发明提供了基于以下反应方程式生产化合物（5）的工艺过程。